Bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant

Drug Metabolism and Disposition

Volumn 39, Issue 10, 2011, Pages 1823-1832

  Bergström, Moa Andresen ^a   Isin, Emre M ^a   Castagnoli Jr , Neal ^b   Milne, Claire E ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DRUG METABOLITE; GLUTATHIONE; IMINIUM ION; ION; METHOXYAMINE; POTASSIUM CYANIDE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG ACTIVATION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; LIVER; MALE; MICROSOME; NONHUMAN; OXIDATIVE DEHYDROGENATION; PRIORITY JOURNAL; PROTEIN BINDING; RAT;

ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYLAMINES; MICROSOMES, LIVER; OXIDATION-REDUCTION; PIPERIDINES; POTASSIUM CYANIDE; PROTEIN BINDING; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB1;

RATTUS;

EID: 80053167482     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.039412     Document Type: Article

References (39)

1. Argoti D, Liang L, Conteh A, Chen L, Bershas D, Yu CP, Vouros P, and Yang E (2005) Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Chem Res Toxicol 18:1537-1544. (Pubitemid 41504473)
2. Atkinson A, Kenny JR, and Grime K (2005) Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Dispos 33:1637-1647. (Pubitemid 41539961)
3. Avent KM, DeVoss JJ, and GillamEM(2006) Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites. Chem Res Toxicol 19:914-920. (Pubitemid 44092357)
4. Baillie TA (2008) Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem Res Toxicol 21:129-137.
5. Bauman JN, Kelly JM, Tripathy S, Zhao SX, Lam WW, Kalgutkar AS, and Obach RS (2009) Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from non-hepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem Res Toxicol 22:332-340.
6. Boyd ST and Fremming BA (2005) Rimonabant-a selective CB1 antagonist. Ann Pharmacother 39:684-690.
7. Castagnoli N Jr, Rimoldi JM, Bloomquist J, and Castagnoli KP (1997) Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes. Chem Res Toxicol 10:924-940. (Pubitemid 27418007)
8. Christensen R, Kristensen PK, Bartels EM, Bliddal H, and Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706-1713. (Pubitemid 350100788)
9. Dalton GD, Bass CE, Van Horn CG, and Howlett AC (2009) Signal transduction via cannabinoid receptors. CNS Neurol Disord Drug Targets 8:422-431.
10. Dalvie DK and O'Connell TN (2004) Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes P450, and monoamine oxidases. Drug Metab Dispos 32:49-57. (Pubitemid 38112535)
11. Di Marzo V (2009) The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 60:77-84.
12. Evans DC, Watt AP, Nicoll-Griffith DA, and Baillie TA (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3-16. (Pubitemid 38134055)
13. Franklin MR (1991) Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol 206:559-573.
14. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, Skordos KW, et al. (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355-1370.
15. Guengerich FP and MacDonald JS (2007) Applying mechanisms of chemical toxicity to predict drug safety. Chem Res Toxicol 20:344-369. (Pubitemid 46548682)
16. Henness S, Robinson DM, and Lyseng-Williamson KA (2006) Rimonabant. Drugs 66:2109-2119; discussion 2120-2101.
17. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202. (Pubitemid 34575709)
18. Kalgutkar AS and Soglia JR (2005) Minimising the potential for metabolic activation in drug discovery. Expert Opin Drug Metab Toxicol 1:91-142.
19. Markwell MAK, Haas SM, Bieber LL, and Tolbert NE (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87:207-210.
20. Mašič LP (2011) Role of cyclic tertiary amine bioactivation to reactive iminium species: structure toxicity relationship. Curr Drug Metab 12:35-50.
21. Murphy PJ (1973) Enzymatic oxidation of nicotine to nicotine 1′(5′) iminium ion. A newly discovered intermediate in the metabolism of nicotine. J Biol Chem 248:2796-2800.
22. Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, Nakai D, and Okazaki O (2009) A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab Dispos 37:1970-1977.
23. Obach RS and Van Vunakis H (1988) Non-metabolic covalent binding of nicotine-delta 1′(5′)- iminium ion to liver microsomes and sulfhydryl-containing polyamino acids. Biochem Pharmacol 37:4601-4604. (Pubitemid 19006296)
24. Obach RS, Kalgutkar AS, Soglia JR, and Zhao SX (2008) Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol 21:1814-1822.
25. Owens SM, Gunnell M, Laurenzana EM, and Valentine JL (1993) Dose- and time-dependent changes in phencyclidine metabolite covalent binding in rats and the possible role of CYP2D1. J Pharmacol Exp Ther 265:1261-1266. (Pubitemid 23321028)
26. Pertwee RG (2006) Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147 (Suppl 1):S163-S171.
27. Polasek TM and Miners JO (2007) In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol 3:321-329. (Pubitemid 47316027)
28. Riley RJ, Grime K, and Weaver R (2007) Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3:51-66. (Pubitemid 47315418)
29. Sayre LM, Engelhart DA, Nadkarni DV, Manoj Babu MK, Flammang AM, and McCoy GD (1997) The role of iminium-enamine species in the toxication and detoxication of cyclic tertiary amines. NIDA Res Monogr 173:106-127.
30. Shenton JM, Chen J, and Uetrecht JP (2004) Animal models of idiosyncratic drug reactions. Chem Biol Interact 150:53-70. (Pubitemid 39441295)
31. Shigenaga MK, Trevor AJ, and Castagnoli N Jr (1988) Metabolism-dependent covalent binding of (S)-[5-3H]nicotine to liver and lung microsomal macromolecules. Drug Metab Dispos 16:397-402.
32. Thompson RA, Isin EM, Li Y, Weaver R, Weidolf L, Wilson I, Claesson A, Page K, Dolgos H, and Kenna JG (2011) Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem Biol Interact 192:65-71.
33. Uetrecht J (2008) Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 21:84-92.
34. Usui T, Mise M, Hashizume T, Yabuki M, and Komuro S (2009) Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab Dispos 37:2383-2392.
35. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S, and RIO-Europe Study Group (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397. (Pubitemid 40523733)
36. Ward DP, Trevor AJ, Kalir A, Adams JD, Baillie TA, and Castagnoli N Jr (1982) Metabolism of phencyclidine. The role of iminium ion formation in covalent binding to rabbit microsomal protein. Drug Metab Dispos 10:690-695. (Pubitemid 13223708)
37. Zeiger E and Guthrie J (1981) Cyclic hydrazides are mutagenic for Salmonella typhimurium. Mutat Res 91:199-205. (Pubitemid 11154909)
38. Zhang Q, Ma P, Wang W, Cole RB, and Wang G (2005a) In vitro metabolism of diarylpyrazoles, a novel group of cannabinoid receptor ligands. Drug Metab Dispos 33:508-517. (Pubitemid 40393193)
39. Zhang Z, Chen Q, Li Y, Doss GA, Dean BJ, Ngui JS, Silva Elipe M, Kim S, Wu JY, Dininno F, et al. (2005b) In vitro bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: formation of reactive iminium and quinone type metabolites. Chem Res Toxicol 18:675-685. (Pubitemid 40563281)